-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Currently, patients with newly diagnosed and relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are mostly treated with Bruton tyrosine kinase inhibitor (BTKi) and venetoclax
Lymphoma
Recently, the internationally renowned journal "Blood" published the results of a multi-center, open-label Phase 1/2 TRANSCEND CLL 004 (NCT03331198) study in the phase 1 dose escalation phase.
In this study, standard or high-risk CLL/SLL patients who had been treated more than two or three times (including BTKi) received two doses of liso-cel (50×106 or 100×106 CAR+ T cells)
Progression-free survival
Progression-free survivalA total of 25 patients were recruited, of which 23 received liso-cel and were included in the safety analysis
83% of patients have high-risk characteristics and carry TP53 mutations or del (17p)
Progression-free survival of patients grouped by MRD status
Progression-free survival of patients grouped by MRD statusCytokine release syndrome occurred in 74% of patients (9% of grade 3), and 39% of patients had neurological events (22% of grade 3/4)
Among the 22 patients with evaluable efficacy, the total response rate was as high as 82%, of which 45% were complete remission.
Original source:
Original source:Tanya Siddiqi, et al.
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed / refractory CLL or SLL
in this message
